| 1 |
26732192 | Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. | 2016 Jan-Mar |
1 |
| 2 |
27022224 | Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. | 2016 Mar 28 |
1 |
| 3 |
27541605 | Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. | 2016 Dec |
3 |
| 4 |
24849518 | Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype. | 2015 Apr |
4 |
| 5 |
25470790 | Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. | 2015 |
1 |
| 6 |
25764680 | [Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C]. | 2015 Feb |
1 |
| 7 |
26191484 | IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. | 2015 |
2 |
| 8 |
24081655 | Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. | 2014 Feb |
1 |
| 9 |
24117654 | Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. | 2014 Jan |
2 |
| 10 |
24166425 | α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. | 2014 Mar |
1 |
| 11 |
24192751 | Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. | 2014 |
1 |
| 12 |
24287582 | Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. | 2014 Nov |
5 |
| 13 |
24628684 | Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. | 2014 Dec |
1 |
| 14 |
24929144 | KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C. | 2014 Aug |
1 |
| 15 |
25328696 | Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. | 2014 |
1 |
| 16 |
25349647 | Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. | 2014 Oct 27 |
1 |
| 17 |
23321318 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. | 2013 May |
2 |
| 18 |
23328301 | IL28B in the era of direct-acting antivirals for hepatitis C. | 2013 Mar |
1 |
| 19 |
23542783 | Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. | 2013 Jul |
1 |
| 20 |
23861088 | A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. | 2013 Oct |
1 |
| 21 |
24000086 | Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. | 2013 Oct |
2 |
| 22 |
21325786 | Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. | 2012 |
2 |
| 23 |
22212576 | IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? | 2012 Feb |
1 |
| 24 |
22967098 | Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? | 2012 Oct |
1 |
| 25 |
21628662 | IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. | 2011 Jul 1 |
2 |
| 26 |
20648473 | Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. | 2010 Aug |
2 |